VALMID
LOE Approachingethinamate
NDAORALCAPSULE
Approved
Mar 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALMID (ethinamate) is an oral capsule sedative-hypnotic approved in 1955 for short-term management of insomnia and related sleep disorders. The drug works as a central nervous system depressant to facilitate sleep onset and maintenance. It represents a legacy small-molecule therapy from the mid-20th century era of sedative development.
LOE Approaching
Declining commercial footprint with minimal active brand investment; residual teams focused on maintenance and compliance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities linked to VALMID are minimal and primarily defensive in nature, focused on compliance, pharmacovigilance, and orderly commercial wind-down rather than growth or innovation. This product does not serve as a platform for career acceleration and is typically assigned to junior or transitional roles managing legacy portfolios.
Regulatory Compliance Specialist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.